MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 16
Patient Impact
Partners in
progress
The power of
clinical trials
C
linical trials are essential to advancing cancer
care. They help researchers determine whether
new treatments work and whether existing
treatments can be made safer, more precise and less
burdensome for patients. For Patricia Latham, that
mission became personal when she was diagnosed
with breast cancer.
After undergoing surgery, chemotherapy and targeted
therapy at MUSC Hollings Cancer Center, Latham faced
another treatment decision: radiation. She was offered
the opportunity to participate in a national clinical trial,
led at Hollings by radiation oncologist Jennifer Harper,
14 | MUSC Hollings Cancer Center
M.D. The study examined whether women with earlystage HER2-positive breast cancer who responded well
to other treatments could safely avoid radiation.
Latham was randomly assigned to the group that did
not receive radiation. Having worked in clinical research
before retiring, she understood that answering questions
like these requires patients willing to participate
despite uncertainty.
“I was interested right away. Having worked
in research, I know how hard it can be to 昀椀nd
participants who meet the criteria and are
willing to take part.”
Her experience illustrates how clinical trials can help
researchers “right-size” cancer treatment – 昀椀nding
the balance between effectively treating disease and
avoiding unnecessary side effects. It also demonstrates
the critical role patients play in advancing care.
As Harper explained, the treatments helping patients
today exist because earlier patients volunteered for
research. By participating herself, Latham became part
of that continuum, generating evidence that could guide
more personalized treatment for future patients.